PharmaShots | Incisive News in 3 Shots

Subscribe Now

SURPASS-CVOT

Eli Lilly Reports Dosing of its First Patient with Tirzepatide in P-III SURPASS-CVOT Study for Cardiovascular Outcomes

Eli Lilly Reports Dosing of its First Patient with Tirzepatide in P-III SURPASS-CVOT Study for Cardiovascular Outcomes

June 9, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us